The Checkpoint Therapeutics Inc (NASDAQ: CKPT) stock has been one of the notable gainers this week so far having rallied by as much as 20% so far.
While the gains are notable, it should also be noted that there has been no news regarding the company’s business that could have led to such gains. However, in such a situation, it might be a good idea for investors to perhaps take a look at some of the notable developments from the past.
Back in November last year, the targeted oncology firm announced the results from the Phase 1 clinical trial of its product cosibelimab. The product in question is meant for the treatment of patients suffering from advanced cancers.
In addition to that, the results from the trial were also presented at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting that was held in the same month. It was a significant milestone for the company. However, it is now important for investors to perhaps keep an eye out for any news regarding the company in the coming days.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.